3.337

1.78% -0.033

Lexaria Bioscience Corp (LEXX)

Overview News Price History Financials Discussions Forecast Stock Split

Lexaria Bioscience Corp stock is traded at $3.337, with a volume of 1,331. It is down -1.78% in the last 24 hours and down -71.47% over the past month. Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Previous Close:

$3.37

Open:

$3.455

24h Volume:

1,331

Relative Volume:

0.01

Market Cap:

$7.28M

Revenue:

$368.00K

Net Income/Loss:

$-9.54M

P/E Ratio:

-6.9695

EPS:

-0.4788

Net Cash Flow:

$-9.47M

1W Performance:

+2.16%

1M Performance:

-71.47%

6M Performance:

+327.21%

1Y Performance:

+116.34%

1-Day Range:

$3.455

1-Week Range:

$3.08

$3.84

52-Week Range:

$0.35

$14.37

Lexaria Bioscience Corp Stock (LEXX) Company Profile

Name

Lexaria Bioscience Corp

Sector

Healthcare (1074)

Industry

Biotechnology (595)

Phone

250-765-6424

Address

100 - 740 MCCURDY ROAD, KELOWNA

Employee

Twitter

Next Earnings Date

2026-07-13

Latest SEC Filings

LEXX's Discussions on Twitter

Compare LEXX vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LEXX Lexaria Bioscience Corp	3.455	7.10M	368.00K	-9.54M	-9.47M	-0.4788
VRTX Vertex Pharmaceuticals Inc	521.23	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.49	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	193.91	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	958.75	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.30	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Lexaria Bioscience Corp Stock (LEXX) Latest News

Sep 21, 2026

Lexaria Bioscience (LEXX) pays $402K in warrant fees - Stock Titan

Sep 21, 2026

Sep 17, 2026

Lexaria Extends Cash Runway Through 2027 After $7.9 Million Capital Boost - TipRanks

Sep 17, 2026

Lexaria Bioscience Corp (NASDAQ: LEXX) Share Price, LEXX Stock News, LEXX Share Price & Updates - kalkine.com.au

Sep 17, 2026

Lexaria DHT3.0 boosts oral absorption for amycretin and retatrutide - scanx.trade

Sep 17, 2026

Lexaria Bioscience raises $7.9M, extends cash runway to 2027 By Investing.com - Investing.com Australia

Sep 17, 2026

Lexaria Bioscience secures $7.9M to extend cash runway through 2027 - scanx.trade

Sep 17, 2026

Lexaria Bioscience raises $7.9M, extends cash runway to 2027 - Investing.com

Sep 17, 2026

Lexaria Updates Financial Position - Weatherford Democrat

Sep 17, 2026

Lexaria Bioscience Corp. (NASDAQ:LEXX) Adds $7.9M Cash, Guides Runway Through 2027 - TradingView

Sep 17, 2026

A tax refund and financing give Lexaria cash through 2027 - Stock Titan

Sep 17, 2026

Sep 15, 2026

Lexaria Bioscience Corp.Common Stock (NQ: LEXX - The Chronicle-Journal

Sep 15, 2026

Sep 09, 2026

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - Investing News Network

Sep 09, 2026

$5.9 million raised as Lexaria issues new rights to buy shares - Stock Titan

Sep 09, 2026

Lexaria Raises $5.9M in Warrant Exercise Transaction - Minichart

Sep 09, 2026

Lexaria Bioscience Raises $5.9 Million Via Warrant Exercise; Issues New Warrants, Engages Wainwright - TradingView

Sep 09, 2026

Sep 08, 2026

Primer: Lexaria Bioscience (LEXX US)Sep 2026 - Smartkarma

Sep 08, 2026

Lexaria Raises $5.9 Million Via Warrant Exercise and Issues New Warrants - TipRanks

Sep 08, 2026

Lexaria raises $5.9M by exercising warrants at reduced price to fund 2027 operations and R&D. - Pluang

Sep 08, 2026

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - investingnews.com

Sep 08, 2026

Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds - TradingView

Sep 08, 2026

A potential $5.9 million plus a $2.6 million rebate may fund Lexaria's 2027 research - Stock Titan

Sep 08, 2026

LEXX: Introducing DehydraTECH 3.0 - Yahoo Finance

Sep 08, 2026

Sep 04, 2026

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network

Sep 04, 2026

Lexaria to present at H.C. Wainwright Global Investment Conference in September 2026 - Pluang

Sep 04, 2026

A drug-delivery company holds 66 granted patents. Lexaria plans a New York presentation. - Stock Titan

Sep 04, 2026